Follow us on Twitter
twitter icon@FreshPatents


Tetrahydrocannabinol patents

      

This page is updated frequently with new Tetrahydrocannabinol-related patent applications.

Optimized cannabis-based aphrodisiac and mood enhancer
A formulated cannabis product includes a cannabinoid mix and carrier processed by nano-emulsification. The cannabinoid mix in one embodiment includes between 0.1-0.3% cannabinol (cbn).
Rise Research Inc


Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same
Described herein are Δ9-thc prodrugs, methods of making Δ9-thc prodrugs, formulations comprising Δ9-thc prodrugs and methods of using Δ9-thc. One embodiment described herein relates to the transdermal administration of a Δ9-thc prodrug for treating and preventing diseases and/or disorders..
Zynerba Pharmaceuticals, Inc.


Topical treatments incorporating cannabis sp. derived botanical drug product
A topical formulation comprising a cannabis derived botanical drug product, wherein the concentration of tetrahydrocannabinol, cannabidiol, or both in the topical formulation is greater than 2 milligrams per kilogram.. .

Phytoterpenoid facilitation of therapeutic onset and efficacy of sublingual cannabinoid administration
A cannabis plant extract based formulation to aid in stabilizing the therapeutic efficacy of cannabinoid containing treatments in patients affected with neurological diseases that comprises one or more of the following: cannabidiol (cbd), tetrahydrocannabinol (thc), and terpenes; wherein the formulation comprises a high ratio of cbd to thc, with each of those cannabinoids in a relatively high concentration. The formulation also comprises beta-caryophyllene that is used to further aid in neuroprotection by co-modulating cb1 and 2 receptors.
Jc Pharma Inc.


Novel cannabinoid combination therapies for multiple myeloma (mm)
The present invention discloses a cytotoxic cocktail comprising; (a) a therapeutically effective amount of at least one cannabinoid selected from the group consisting of: cannabidiol (cbd) or a derivative thereof, tetrahydrocannabinol (thc) or a derivative thereof, and any combination thereof; and (b) at least one therapeutic agent selected from the group consisting of: bortezomib (btz), carflizomib (cfz), lenalidomide (len), dexamethasone (dex), melphalan (mel) and doxorubicin (doxo). In a core embodiment the cocktail is conferring a synergistic effect with respect to inhibition or cytotoxicity of multiple myeloma (mm) cells, relative to said at least one therapeutic agent selected from the group consisting of: btz, cfz, len, dex, mel, doxo and said cbd and thc, administered separately in a similar concentration..
One World Cannabis Ltd


Apparatus and methods for biosynthetic production of cannabinoids
The present invention provides an apparatus and methods for producing tetrahydrocannabinolic acid (thca), cannabichromenic acid (cbca) and cannabichromenic acid (cbca) in different ratios. The apparatus comprises: (i) a bioreactor comprising (a) an automated supply system configured to deliver a first automated supply of cannabigerolic acid (cbga), a cannabinoid acid synthase, and a reaction mixture; and (b) a second automated system to cease the reaction; (ii) a controller configured to modify a property of the reaction mixture to produce the desired products; and (iii) an extractor configured to recover the tetrahydrocannabinolic acid (thca), cannabichromenic acid (cbca) or cannabidiolic acid (cbda) and cannabichromenic acid..
Teewinot Technologies Limited


Ultrapure tetrahydrocannabinol-11-oic acids
This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis.. .
Corbus Pharmaceuticals, Inc.


Alimentary composition comprised of insects and tetrahydrocannabinol
Variable-scale, modular, easily manufacturable, energy efficient, reliable, and computer operated insect production superstructure systems (ipss) may be used to produce insects for human and animal consumption, and for the extraction and use of lipids for applications involving medicine, nanotechnology, consumer products, and chemical production with minimal water, feedstock, and environmental impact. An ipss may comprise modules including feedstock mixing, enhanced feedstock splitting, insect feeding, insect breeding, insect collection, insect grinding, pathogen removal, multifunctional flour mixing, and lipid extraction.
Insectergy, Llc


Non-aqueous delta9-tetrahydrocannabinol oral liquid formulations
The present invention discloses a means to improve stability, dissolution, and in vivo bioavailability of non-aqueous oral formulations containing natural or synthetic cannabinoid derivatives. In particular, this invention provides a non-aqueous cannabinoid formulation containing zero amount of water with one or more organic solvents, surfactants, co-surfactants, semi-polar solvents and mono-di glycerides.
Ascent Pharmaceuticals, Inc.


"pobelch - Gle" Ood
. .

. .

Method for preparation of a cannabinoid extract from hemp

The method consists in that the extract, obtained in accordance with various methods, undergoes a centrifugal countercurrent liquid-liquid chromatography, as the operation includes a centrifugation of solvents and the extract, obtained during the previous operations; the solvents form two phases, the phase, which the extract is dissolved in, is mobile, and the other one is stationary, whereby the mobile phase passes through the stationary phase, wherein several amounts of the components of the extract content are captured; this passing of the mobile phase through the stationary phase is repeated many times, until separation of the desired substances, which are analyzed in a familiar way, whereby as stationary phase solvents are used, which are selected from the group of straight-chain and branched-chain hydrocarbons, produced from crude oil, straight-chain and/or branched-chain alcohols, straight-chain and/or branched-chain ketones, straight-chain and/or branched chain carboxylic acids, straight-chain and/or branched-chain nitriles, gases in supercritical and subcritical condition, like carbon dioxide, nitrogen, nitrogen oxides, water with modified acidity with or without salts of organic and non-organic substances dissolved therein, as for example naso3, carbonate compounds or mixtures of the above-mentioned solvents, and as mobile phase solvents are used, which are selected from the group of straight-chain and branched-chain hydrocarbons, produced from crude oil, straight-chain and/or branched-chain alcohols, straight-chain and/or branched-chain ketones, straight-chain and/or branched chain carboxylic acids, straight-chain and/or branched-chain nitriles, gases in supercritical and subcritical condition, like carbon dioxide, nitrogen, nitrogen oxides, water with modified acidity by organic and/or inorganic acids and bases, as well as lewis acids and bases in the interval from 0 to 14 ph, with or without salts of organic and non-organic substances dissolved therein, as for example naso3, carbonate compounds, or mixtures of the above-mentioned solvents, while the choice of the solvents between the two phases is conditional on that, they shall be different and immiscible with each other; the centrifugation revolutions and the flow speed of the mobile phase are designed (calculated or determined experimentally) depending on the total phase volume; thus at the finish of the process the tetrahydrocannabinols and/or the tetrahydrocannabinol acids are separated from the remaining cannabinoids and/or cannabinoid acids in the solution, the other cannabinoids in the process can also be separated as a pure substance, separate in a solution and the solvents are evaporated respectively, in order to obtain a pure substance.. .

Plant extract from low-thc cannabis for the treatment of disease

The present invention relates to a plant extract from a low-tetrahydrocannabinol (thc) variety of cannabis sativa subsp. Sativa for the treatment of disease.

Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids

This invention is in the field of medicinal chemistry and relates to novel compounds, and pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring/wound healing abnormalities, post operative adhesions, and reactive fibrosis. The invention also relates to methods of using the compounds and pharmaceutical compositions of this invention to treat fibrotic conditions..
Corbus Pharmaceuticals, Inc.

Method for making coffee products containing cannabis ingredients

The present disclosure is directed to methods of making a coffee products containing cannabinoids that are extracted from cannabis plant. According to one embodiment, the method includes the steps of (a) extracting cannabinoids from cannabis plant; and (b) admixing the cannabinoids into a coffee product.
Imbue Llc

Method and composition for acute treatment of seizures

A nasal spray composition and method for treating convulsive seizures, including epileptic seizures, and also autism behavioral events. In embodiments, the nasal spray composition contains delta-9-tetrahydrocannabinol and, optionally, terpenes such as linalool..
Jc Pharma, Inc.

Enkephalin-influencing composition and method

A composition which includes phenylalanine, serine, glutamine and gaba (γ-aminobutyric acid). The composition contains the essential amino acids phenylalanine; glutamine; the non-essential amino acid serine; and gaba (γ-aminobutyric acid) in concentrations effective to influence or modulate the neurotransmitter pentapeptide enkephalin.
Bioadatp, Llc

Cannabis-based extracts and topical formulations for use in skin disorders

The present invention discloses a pharmaceutical topical composition comprising cannabidiol (cbd) or a derivative thereof and tetrahydrocannabinol (thc) or a derivative thereof in an about 1:1 ratio, useful for treatment or prevention of inflammatory skin disorders, and treatment methods thereof.. .
One World Cannabis Ltd

Methods for treatment of cognitive decline

Embodiments of the invention relate to methods for treatment of age-related cognitive decline in a patient comprising administering to the patient a low dose of tetrahydrocannabinol (thc), preferably in an amount of 10-400 micrograms (μg). Thc may be administered in a variety of routes.
Ramot At Tel Aviv University Ltd.

Cannabis plant named 'midnight'

The disclosure relates to a new and distinct cannabis sativa l. Plant named ‘midnight’, having an almost equal ratio of cannabidiol (cbd) concentration to tetrahydrocannabinol (thc) concentration, (e.g., substantially close to 1), as illustrated and described herein..

Cannabis plant named 'avidekel'

The disclosure relates to a new and distinct cultivar of cannabis sativa plant named ‘avidekel’, characterized by a high amount of cannabidiol (cbd) (16.3%) and a very low amount of tetrahydrocannabinol (thc, 0.8%).. .

Enkephalin-influencing composition and method

A composition which includes phenylalanine, serine, glutamine and gaba (γ-aminobutyric acid). The composition contains the essential amino acids phenylalanine; glutamine; the non-essential amino acid serine; and gaba (γ-aminobutyric acid) in concentrations effective to influence or modulate the neurotransmitter pentapeptide enkephalin.
Bioadatp, Llc

Apparatus and methods for biosynthetic production of cannabinoids

The present invention provides an apparatus and methods for producing tetrahydrocannabinolic acid (thca), cannabichromenic acid (cbca) and cannabichromenic acid (cbca) in different ratios. The apparatus comprises: (i) a bioreactor comprising (a) an automated supply system configured to deliver a first automated supply of cannabigerolic acid (cbga), a cannabinoid acid synthase, and a reaction mixture; and (b) a second automated system to cease the reaction; (ii) a controller configured to modify a property of the reaction mixture to produce the desired products; and (iii) an extractor configured to recover the tetrahydrocannabinolic acid (thca), cannabichromenic acid (cbca) or cannabidiolic acid (cbda) and cannabichromenic acid..
Full Spectrum Laboratories Limited

Cannabis separation

Provided are a cannabis composition in pellet form, a method of preparing a cannabis composition in pellet form, a method of separating a plant resin from a harvested plant material, a method of treatment with a cannabis composition in pellet form, and a kit including a cannabis composition in pellet form. For example, the cannabis composition in pellet form may include a cannabinoid resin.

Cannabis pellets

A cannabis composition in pellet form, a method of preparing a cannabis composition in pellet form, a method of separating a plant resin from a harvested plant material, a method of treatment with a cannabis composition in pellet form, and a kit including a cannabis composition in pellet form are provided. The cannabis composition in pellet form may include a cannabinoid resin.

Cannabis plant named 'katelyn faith'

The disclosure is directed to a new and distinct cultivar of cannabis sativa plant named ‘katelyn faith’, characterized by a high amount of cannabidiol (cbd)(13.5%) and a low amount of tetrahydrocannabinol (thc)(0.4%). .
Syngenta Participations Ag

Composition of olivetol and use to reduce or inhibit the effects of tetrahydrocannabinol in the human body

Embodiments of the present invention relate to the use of a therapeutically-effective amount of olivetol to reduce, eliminate, inhibit or alleviate the psychoactive effects of thc in users of cannabis. Further embodiments of the present invention relate to a softgel, tablet or capsule of olivetol in combination with an edible oil..

Composition of olivetol and use to reduce or inhibit the effects of tetrahydrocannabinol in the human body

Embodiments of the present invention relate to the use of a therapeutically-effective amount of olivetol to reduce, eliminate, inhibit or alleviate the psychoactive effects of thc in users of cannabis. Further embodiments of the present invention relate to a softgel, tablet or capsule of olivetol in combination with an edible oil..

Method for making coffee products containing cannabis ingredients

The present disclosure is directed to methods of making a coffee products containing cannabinoids that are extracted from cannabis plant. According to one embodiment, the method includes the steps of (a) extracting cannabinoids from cannabis plant; and (b) admixing the cannabinoids into a coffee product.

Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same

Described herein are Δ9-thc prodrugs, methods of making Δ9-thc prodrugs, formulations comprising Δ9-thc prodrugs and methods of using Δ9-thc. One embodiment described herein relates to the transdermal administration of a Δ9-thc prodrug for treating and preventing diseases and/or disorders..
Zynerba Pharmaceuticals, Inc.

Method and system for extracting compounds from plants and plant based materials

The invention provides a method and system for extracting desired compounds from a plant or a plant based material featuring a) providing a plant or plant based material; b) pumping co2 gas from a co2 storage vessel into an apparatus containing a co2 circulation loop; c) circulating co2 through the plant or plant based material in the circulation loop; d) extracting the desired compounds; and e) discharging the co2 gas from the co2 circulation loop. The circulation loop may have a separator vessel and an extractor vessel, the desired compound may be a terpene, tetrahydrocannabinol (thc) or carbenoxolone (cbx), and the co2 may be circulated as a supercritical co2.
Mrx Xtractors Llc

Ultrapure tetrahydrocannabinol-11-oic-acids

This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis.. .
Corbus Pharmaceuticals, Inc.

Ultrapure tetrahydrocannabinol-11-oic acids

This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis.. .
Corbus Pharmaceuticals, Inc.

Ultrapure tetrahydrocannabinol-11-oic acids

This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis.. .
Corbus Pharmaceuticals, Inc.

Cannabinoid composition and treating pain

A combination of thc, cbd and cobalamin (in a ratio of about 63%, 27% and 10%, respectively) is used with a topical carrier such as shea butter cream to relieve pain. The thc and cbd mixture is extracted from a cannabis indica dominant strain using high pressure and carbon dioxide (co2) as a solvent and comprises: tetrahydrocannabinol “thc” (9-tetrahydrocannabinol (delta-9 thc), 8-tetrahydrocannabinol (delta-8 thc) and 9-thc acid), cannabidiol “cbd”, cannabinol “cbn”, cannabichromene (“cbc”), cannabigerol (“cbg”), terpenoids and flavonoids.
India Globalization Capital, Inc.

Compositions, dosages, and methods of using tetrahydrocannabinol derivatives

Dosage forms of compounds of formula i, e.g., ajulemic acid, and methods of delivering these compounds and using these compounds to treat or prevent a cb1/cb2 associated disease are disclosed.. .
Corbus Pharmaceuticals, Inc.

Method for increasing cannabinol content in a lipid-based extract of cannabis

A method for modifying cannabinol (cbn) to trans-Δ9-tetrahydrocannabinol (thc) content in a lipid-based extract of cannabis to yield a low-thc product. The method includes providing a lipid-based extract of cannabis containing thc, heating the lipid-based extract at 1 atm of pressure to 157 to 160° c.
Raderman Holdings, Llc

Process for the production of cannabidiol and delta-9-tetrahydrocannabinol

The present disclosure relates to the preparation of a cannabidiol compound or a derivative thereof. The cannabidiol compound or derivatives thereof can be prepared by an acid-catalyzed reaction of a suitably selected and substituted di-halo-olivetol or derivative thereof with a suitably selected and substituted cyclic alkene to produce a dihalo-cannabidiol compound or derivative thereof.
Noramco, Inc.

Process for the production of cannabidiol and delta-9-tetrahydrocannabinol

The present disclosure relates to the preparation of a cannabidiol compound or a derivative thereof. The cannabidiol compound or derivatives thereof can be prepared by an acid-catalyzed reaction of a suitably selected and substituted di-halo-olivetol or derivative thereof with a suitably selected and substituted cyclic alkene to produce a dihalo-cannabidiol compound or derivative thereof.
Noramco, Inc.

Anti-microbial composition comprising cannabinoids

This invention discloses anti-bacterial and anti-fungal compositions in spray form, in cream form, in liquid form, and in powder form. The anti-bacterial and anti-fungal compositions comprise cannabinoids, specifically cannabidiol, cannabigerol, tetrahydrocannabinol, tetracannabidivarin, and/or cannabidivarin for anti-bacterial and anti-fungal activities.
Axim Biotechnologies, Inc.

Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids

This invention is in the field of medicinal chemistry and relates to novel compounds, and pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring/wound healing abnormalities, post operative adhesions, and reactive fibrosis. The invention also relates to methods of using the compounds and pharmaceutical compositions of this invention to treat fibrotic conditions..
Corbus Pharmaceuticals Inc.

Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis

The invention relates to the use of a combination of cannabinoids for the treatment of pain, inflammation and/or disease modification in arthritis. Preferably the cannabinoids are selected from cannabidiol (cbd) or cannabidivarin (cbdv) and delta-9-tetrahydrocannabinol (thc) or tetrahydrocannabinovarin (thcv).
Gw Pharma Limited

Apparatus and methods for biosynthetic production of cannabinoids

The present invention provides an apparatus and methods for producing tetrahydrocannabinolic acid (thca), cannabichromenic acid (cbca) and cannabichromenic acid (cbca) in different ratios. The apparatus comprises:(i) a bioreactor comprising (a) an automated supply system configured to deliver a first automated supply of cannabigerolic acid (cbga), a cannabinoid acid synthase, and a reaction mixture; and (b) a second automated system to cease the reaction; (ii) a controller configured to modify a property of the reaction mixture to produce the desired products; and (iii) an extractor configured to recover the tetrahydrocannabinolic acid (thca), cannabichromenic acid (cbca) or cannabidiolic acid (cbda) and cannabichromenic acid..
Full Spectrum Laboratories Limited

Process to extract and purify delta-9-tetrahydrocannabinol

Δ9-thc acid is extracted from cannabis flowers using a first organic solvent, then separated using a second aqueous solvent. Δ9-thc acid is converted to Δ9-thc carboxylic salt before being extracted by a third organic solvent and converted back to Δ9-thc carboxylic acid.
Axim Biotechnologies, Inc.

Uses of cannabidiol for treatment of infantile spasms

In some aspects, the invention relates to a method of treating or preventing infantile spasms in a subject, comprising administering to the subject a composition comprising cannabidiol (“cbd”). In certain preferred embodiments, the composition comprising cbd is substantially devoid of tetrahydrocannabinol (“thc”)..

Axillary transdermal compound delivery system

A deodorant stick drug delivery system has one or more hydrophilic carriers, water, one or more gelling agents, an active ingredient, and a solvent. The active ingredient may be cannabinoids, nicotine, caffeine, vitamins, insulin and tetrahydrocannabinol.

Composition with pharmacological effect for vaporizing and method

A composition is provided that includes a cannabinoid capable of inducing a pharmacological effect, an ester, a condensation aerosol, and a carrier liquid solution of food grade materials. The cannabinoid may include a bio-active ingredient receivable by a cannabinoid receptor and/or an acetylcholine receptor.

Compressed tablet containing delta 9-tetrahydrocannabinol, its manufacture and use of such tablet in oral treatment

The present invention relates to compressed tablets for peroral delivery of the cannabinoid Δ9-tetrahydrocannabinol (thc). More particularly, the invention provides a compressed tablet having a tablet weight of 25-1000 mg, said tablet being composed of: compressed tablet containing delta 9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment 30-90 wt % of a granulate; 10-70 wt % of lactose; and 0-30 wt % of other tablet excipients; wherein the granulate contains: a.
Echo Pharmaceuticals B.v.

Methods for purifying trans-(-)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9 tetrahydrocannabinol

Methods for making trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ9-tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-Δ9-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(−)-Δ9-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(−)-Δ9-tetrahydrocannabinol based on the total amount of trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol.
Svc Pharma Lp

Novel fertilizer

The present invention is directed to a fertilizer composition comprising a cannabidiol (cbd oil), and/or a tetrahydrocannabinol (thc oil) and/or hemp oil derivatives in combination with a superabsorbent polymer(s) (sap's). The present invention also relates to methods of using and manufacturing said fertilizers..

Methods for purifying trans-(-)-delta9-tetrahydrocannabinol and trans-(+)-delta9-tetrahydrocannabinol

Methods for making trans-(−)-Δ9-tetrahydrocannabinoi and trans-(+)-Δ9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ9-tetrahydrocannabinoi composition is prepared by allowing a composition comprising (±)-Δ9-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(−)-Δ9-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(−)-Δ9-tetrahydrocannabinol based on the total amount of trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol.

Methods for purifying trans-(-)-delta9-tetrahydrocannabinol and trans-(+)-delta9-tetrahydrocannabinol

Methods for making trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ9-tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-Δ9-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(−)-Δ9-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(−)-Δ9-tetrahydrocannabinol based on the total amount of trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol.

System and determining a concentration of a compound in a solvent

The present describes a system and method for determining the concentration of tetrahydrocannabinol (thc) including a tray comprising a first analyte including an infusion of a solvent and cannabis, a light emitting element configured to illuminate the first analyte, a light receiving element configured to receive a first light transmitted through the first analyte, and a control circuit configured to calculate a concentration of tetrahydrocannabinol in the first analyte based at least in part on the first light.. .
Engineered Medical Technologies

Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitvity in the treatment of a brain tumour

The present invention relates to the use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer. Preferably the phytocannabinoids used are either tetrahydrocannabinol (thc) and/or cannabidiol (cbd).
Otsuka Pharmaceutical Co. Limited

Cannabis plant named 'midnight'

The disclosure relates to a new and distinct cannabis sativa l. Plant named ‘midnight’, having an almost equal ratio of cannabidiol (cbd) concentration to tetrahydrocannabinol (thc) concentration, (e.g., substantially close to 1), as illustrated and described herein..
Corn Bak B.v.

Cannabis plant named 'erez'

The disclosure relates to a new and distinct cultivar of cannabis sativa plant named ‘erez’, characterized by a high amount of cannabidiol (cbd) (>16%) and a higher amount of tetrahydrocannabinol (thc, ˜23%).. .
Corn Bak B.v.

Cannabis plant named 'avidekel'

The disclosure relates to a new and distinct cultivar of cannabis sativa plant named ‘avidekel’, characterized by a high amount of cannabidiol (cbd) (16.3%) and a very low amount of tetrahydrocannabinol (thc, 0.8%).. .
Corn Bak B.v.

Alternative solutions for the administration of cannabis derived botanical products

Compositions comprising: (a) at least one polyvinylpyrrolidone/vinyl acetate copolymer that forms an open matrix network; and (b) at least one ingredient tetrahydrocannabinol and cannabidiol present within the open matrix network.. .

Method for making coffee products containing cannabis ingredients

The present disclosure is directed to methods of making a coffee products containing cannabinoids that are extracted from cannabis plant. According to one embodiment, the method includes the steps of (a) extracting cannabinoids from cannabis plant; and (b) admixing the cannabinoids into a coffee product.
Imbue Llc